Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Exercise training prevents obesity-associated disorders: Role of miRNA-208a and MED13.

Fernandes T, Barretti DL, Phillips MI, Menezes Oliveira E.

Mol Cell Endocrinol. 2018 Nov 15;476:148-154. doi: 10.1016/j.mce.2018.05.004. Epub 2018 May 7.

PMID:
29746886
2.

Antisense Therapy for Cardiovascular Diseases.

Phillips MI, Costales J, Lee RJ, Oliveira E, Burns AB.

Curr Pharm Des. 2015;21(30):4417-26. Review.

PMID:
26234793
3.

Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs.

Fernandes T, Baraúna VG, Negrão CE, Phillips MI, Oliveira EM.

Am J Physiol Heart Circ Physiol. 2015 Aug 15;309(4):H543-52. doi: 10.1152/ajpheart.00899.2014. Epub 2015 Jun 12. Review.

4.

Infrared fluorescent protein 1.4 genetic labeling tracks engrafted cardiac progenitor cells in mouse ischemic hearts.

Chen L, Phillips MI, Miao HL, Zeng R, Qin G, Kim IM, Weintraub NL, Tang Y.

PLoS One. 2014 Oct 30;9(10):e107841. doi: 10.1371/journal.pone.0107841. eCollection 2014.

5.

Tumor-free iPS stem cells for heart cells.

Phillips MI.

Cell Cycle. 2014;13(10):1519. doi: 10.4161/cc.28894. Epub 2014 Apr 22. No abstract available.

6.

Genetically reprogrammed, liver-derived insulin-producing cells are glucose-responsive, but susceptible to autoimmune destruction in settings of murine model of type 1 diabetes.

Tang DQ, Shun L, Koya V, Sun Y, Wang Q, Wang H, Li SW, Sun Y, Purich DL, Zhang C, Hansen B, Qian K, Atkinson M, Phillips MI, Yang LJ.

Am J Transl Res. 2013;5(2):184-99. Epub 2013 Mar 28.

7.

Genetic modification of stem cells for cardiac, diabetic, and hemophilia transplantation therapies.

Phillips MI, Tang Y.

Prog Mol Biol Transl Sci. 2012;111:285-304. doi: 10.1016/B978-0-12-398459-3.00013-7. Review.

PMID:
22917236
8.

Gene, stem cell, and future therapies for orphan diseases.

Phillips MI.

Clin Pharmacol Ther. 2012 Aug;92(2):182-92. doi: 10.1038/clpt.2012.82. Epub 2012 Jun 27. Review.

PMID:
22739143
9.

What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.

Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA.

Pediatrics. 2012 Mar;129(3):516-21. doi: 10.1542/peds.2011-1798. Epub 2012 Feb 27.

PMID:
22371464
10.

Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis.

DA Silva ND Jr, Fernandes T, Soci UP, Monteiro AW, Phillips MI, DE Oliveira EM.

Med Sci Sports Exerc. 2012 Aug;44(8):1453-62. doi: 10.1249/MSS.0b013e31824e8a36.

PMID:
22330028
11.

Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: role of microRNAs-16, -21, and -126.

Fernandes T, Magalhães FC, Roque FR, Phillips MI, Oliveira EM.

Hypertension. 2012 Feb;59(2):513-20. doi: 10.1161/HYPERTENSIONAHA.111.185801. Epub 2012 Jan 3.

PMID:
22215713
12.

LOX-1 and angiotensin receptors, and their interplay.

Wang X, Phillips MI, Mehta JL.

Cardiovasc Drugs Ther. 2011 Oct;25(5):401-17. doi: 10.1007/s10557-011-6331-7. Review.

PMID:
21861069
13.

Combinatorial treatment of bone marrow stem cells and stromal cell-derived factor 1 improves glycemia and insulin production in diabetic mice.

Cheng H, Zhang YC, Wolfe S, Valencia V, Qian K, Shen L, Tang YL, Hsu WH, Atkinson MA, Phillips MI.

Mol Cell Endocrinol. 2011 Oct 15;345(1-2):88-96. doi: 10.1016/j.mce.2011.07.024. Epub 2011 Jul 27.

14.

Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7).

Fernandes T, Hashimoto NY, Magalhães FC, Fernandes FB, Casarini DE, Carmona AK, Krieger JE, Phillips MI, Oliveira EM.

Hypertension. 2011 Aug;58(2):182-9. doi: 10.1161/HYPERTENSIONAHA.110.168252. Epub 2011 Jun 27.

15.

MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats.

Soci UP, Fernandes T, Hashimoto NY, Mota GF, Amadeu MA, Rosa KT, Irigoyen MC, Phillips MI, Oliveira EM.

Physiol Genomics. 2011 Jun 15;43(11):665-73. doi: 10.1152/physiolgenomics.00145.2010. Epub 2011 Mar 29.

16.

Therapies for inborn errors of metabolism: what has the orphan drug act delivered?

Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR.

Pediatrics. 2010 Jul;126(1):101-6. doi: 10.1542/peds.2009-3246. Epub 2010 Jun 21.

PMID:
20566615
17.

Orphan products: an emerging trend in drug approvals.

Coté T, Kelkar A, Xu K, Braun MM, Phillips MI.

Nat Rev Drug Discov. 2010 Jan;9(1):84. doi: 10.1038/nrd2546-c1. No abstract available.

PMID:
20043031
18.

Growth differentiation factor 15 and coronary collateral formation.

Sun T, Huang Y, Phillips MI, Luo X, Zhu J, Shi H, Li J.

Clin Cardiol. 2010 Jan;33(1):E1-5. doi: 10.1002/clc.20698.

19.

Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression.

Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G.

Circ Res. 2009 May 22;104(10):1209-16. doi: 10.1161/CIRCRESAHA.109.197723. Epub 2009 Apr 30.

20.

Stem cell therapy for heart failure: the science and current progress.

Phillips MI, Tang YL, Pinkernell K.

Future Cardiol. 2008 May;4(3):285-98. doi: 10.2217/14796678.4.3.285.

PMID:
19804333
21.

Brain renin angiotensin in disease.

Phillips MI, de Oliveira EM.

J Mol Med (Berl). 2008 Jun;86(6):715-22. doi: 10.1007/s00109-008-0331-5. Epub 2008 Apr 2. Review.

PMID:
18385968
22.

Genetic modification of stem cells for transplantation.

Phillips MI, Tang YL.

Adv Drug Deliv Rev. 2008 Jan 14;60(2):160-72. Epub 2007 Oct 11. Review.

23.

A novel two-step procedure to expand cardiac Sca-1+ cells clonally.

Tang YL, Shen L, Qian K, Phillips MI.

Biochem Biophys Res Commun. 2007 Aug 10;359(4):877-83. Epub 2007 Jun 11.

24.

Efficient and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus type 8.

Cheng H, Wolfe SH, Valencia V, Qian K, Shen L, Phillips MI, Chang LJ, Zhang YC.

J Biomed Sci. 2007 Sep;14(5):585-94. Epub 2007 Mar 27.

PMID:
17387636
25.

Invited commentary.

Tang YL, Phillips MI.

Ann Thorac Surg. 2007 Apr;83(4):1499-500. No abstract available.

PMID:
17383365
26.

Commentary: The seven challenges of stem cell education in biochemistry.

Schuster SM, Phillips MI.

Biochem Mol Biol Educ. 2007 Jan;35(1):73. doi: 10.1002/bmb.18. No abstract available.

27.

Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia.

Arnold AS, Tang YL, Qian K, Shen L, Valencia V, Phillips MI, Zhang YC.

J Hypertens. 2007 Jan;25(1):197-205.

PMID:
17143192
28.

A vigilant, hypoxia-regulated heme oxygenase-1 gene vector in the heart limits cardiac injury after ischemia-reperfusion in vivo.

Tang YL, Qian K, Zhang YC, Shen L, Phillips MI.

J Cardiovasc Pharmacol Ther. 2005 Dec;10(4):251-63.

PMID:
16382261
29.

Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector.

Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI.

J Am Coll Cardiol. 2005 Oct 4;46(7):1339-50.

30.

Gene therapy for hypertension: antisense inhibition of the renin-angiotensin system.

Phillips MI, Kimura B.

Methods Mol Med. 2005;108:363-79.

PMID:
16028695
31.

Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction.

Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, Phillips MI.

Ann Thorac Surg. 2005 Jul;80(1):229-36; discussion 236-7.

PMID:
15975372
32.

A hypoxia-inducible vigilant vector system for activating therapeutic genes in ischemia.

Tang YL, Tang Y, Zhang YC, Agarwal A, Kasahara H, Qian K, Shen L, Phillips MI.

Gene Ther. 2005 Aug;12(15):1163-70.

PMID:
15800659
33.
34.

Antisense therapeutics for hypertension: targeting the renin-angiotensin system.

Phillips MI, Kimura B.

Methods Mol Med. 2005;106:51-68. Review. No abstract available.

PMID:
15375312
35.

Antisense inhibition: oligonucleotides, ribozymes, and siRNAs.

Zhang YC, Taylor MM, Samson WK, Phillips MI.

Methods Mol Med. 2005;106:11-34. Review. No abstract available.

PMID:
15375310
36.

Antisense therapeutics: a promise waiting to be fulfilled.

Phillips MI.

Methods Mol Med. 2005;106:3-10. Review. No abstract available.

PMID:
15375309
38.

Neuroprotective action of halogenated derivatives of L-phenylalanine.

Kagiyama T, Glushakov AV, Sumners C, Roose B, Dennis DM, Phillips MI, Ozcan MS, Seubert CN, Martynyuk AE.

Stroke. 2004 May;35(5):1192-6. Epub 2004 Apr 8.

PMID:
15073406
39.

Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system.

Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI.

Hypertension. 2004 Apr;43(4):746-51. Epub 2004 Feb 23.

PMID:
14981066
40.

Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium.

Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, Yang YZ, Pan C, Ge J, Phillips MI.

Regul Pept. 2004 Jan 15;117(1):3-10.

PMID:
14687695
41.

Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy.

Kagiyama S, Qian K, Kagiyama T, Phillips MI.

Hypertension. 2003 Mar;41(3 Pt 2):824-9. Epub 2002 Dec 2.

PMID:
12624003
43.

Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats.

Kagiyama T, Kagiyama S, Phillips MI.

Regul Pept. 2003 Feb 28;110(3):241-7.

PMID:
12573806
44.

The predominant role of brain angiotensinogen and angiotensin in environmentally induced hypertension.

Peng J, Kimura B, Phillips MI.

Regul Pept. 2002 Dec 31;110(1):25-32.

PMID:
12468106
45.
46.
47.

Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense.

Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI.

Circulation. 2002 Aug 20;106(8):909-12.

PMID:
12186792
48.

Angiotensin II as a pro-inflammatory mediator.

Phillips MI, Kagiyama S.

Curr Opin Investig Drugs. 2002 Apr;3(4):569-77. Review.

PMID:
12090726
49.

Gene therapy for hypertension: the preclinical data.

Phillips MI.

Methods Enzymol. 2002;346:3-13.

PMID:
11883075
50.

Hypoxia inducible double plasmid system for myocardial ischemia gene therapy.

Tang Y, Jackson M, Qian K, Phillips MI.

Hypertension. 2002 Feb;39(2 Pt 2):695-8.

PMID:
11882633

Supplemental Content

Loading ...
Support Center